Darapladib is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis.

[1] It was discovered by Human Genome Sciences in collaboration with GlaxoSmithKline (GSK).

[2] In November 2013, GSK announced that the drug had failed to meet Phase III endpoints in a trial of 16,000 patients with acute coronary syndrome (ACS).

[5] The authors present data that the original target of Darapladib, Lp-PLA2, is absent in the host red blood cell.

This drug article relating to the cardiovascular system is a stub.